Heart failure & cardiomyopathies
First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy
Authors' conclusion
TA-BSM is a safe and efficient minimally invasive procedure for septal reduction of heterogeneous HOCM.
Study context
- Population
- Patients with hypertrophic obstructive cardiomyopathy (HOCM) and drug-refractory disabling symptoms, aged 12 to 77 years46 followed 3 months
- Participants
- 47 patients
- Outcome
- Procedural success: resting/provoked LVOT gradient <30/50 mm Hg and residual MR grade ≤1+ (of 4+)
- Follow-up
- 3 months
Main finding
As reported in the abstract
Procedural success (resting/provoked LVOT gradient <30/50 mm Hg and residual MR grade ≤1+)
- Procedural success among 46 patients followed for 3 months
- 42
Further findings
Maximal left ventricular outflow tract (LVOT) gradient · baseline vs 3 months
mm Hg
- Baseline, median (IQR 67-114 mm Hg)
- 86
- 3 months, median (IQR 14-28 mm Hg)
- 19
Mitral regurgitation (MR) grade ≤1+ · baseline vs 3 months
- Patients with MR grade ≤1+ at baseline
- 3
- Patients with MR grade ≤1+ at 3 months
- 45
Death and major adverse events
- Death on postoperative day 10 (device-unrelated)
- 1
- Delayed ventricular septal perforation
- 1
- Intraoperative LV apical tear
- 1
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol. Published 15 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →